The report provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.
The growth in this market will majorly be driven by the increasing production of biologics and large molecules, as depth filtration plays a significant role in providing pure and quality products. Depth filters offer advantages such as low cost and ease of use; these advantages are driving their uptake in the market. However, low capacity of depth filters for high-density harvest is a key challenge in this market.
Furthermore, based on application, the depth filtration market is categorized into final product processing, cell clarification, raw material filtration, and other applications. In 2017, final product processing segment is expected to account the largest share of the global depth filtration market. The final product processing segmented is further divided into small molecule processing and biologics processing. The large share of the final product processing segment is attributed to the rapid growth in the biopharmaceutical industry, expansion in generics production, and the need for high-quality final products.
North America (comprising the U.S. and Canada) is expected to account for the largest share of the global depth filtration market in 2017, followed by Europe. North America is the world’s largest pharmaceutical market and a leader in biopharmaceutical research. Rising quality requirements have emphasized the need for advanced bioproduction technology in this region. Asia-Pacific is expected to grow at the highest CAGR in the forecast period. Significant investments by key market players, increasing government support, developing R&D infrastructure, and growing expertise and academic excellence are the major factors fueling the growth of the depth filtration market in the Asia-Pacific region.
The depth filtration market is dominated by established players such as Merck KGaA (Germany), Sartorius Stedim Biotech S.A. (France), and Pall Corporation (U.S.).
The Metabolomics Market is expected to grow at a CAGR of 14.6% during the forecast period (2016–2021) to reach USD 2.39 Billion by 2021.
According to the new market research report “Metabolomics Market by Product (GC, HPLC, UPLC, NMR, Mass Spectrometry, Surface-based mass analysis, Bioinformatics), Application (Biomarker & Drug Discovery, Nutrigenomics, Toxicology), Indication (Oncology, Cardiology, Inborn Errors) — Forecast to 2021”, published by MarketsandMarkets™. The global metabolomics market was valued at USD 1.03 Billion in 2016.
The metabolomics market has witnessed significant growth primarily due to the increasing need advanced technologies. However, need for well-qualified researchers, issues related to data examination and processing, and the high cost of tools and instruments are restraining the growth of this market.
In this report, the market is majorly segmented by product and service, application, indication, and region. Based on product and service, the market is segmented into metabolomics instruments and metabolomics bioinformatics tools & services. The metabolomics instruments segment accounted for largest share of global metabolomics market in 2015. The metabolomics bioinformatics tools & services segment is expected to grow at the highest CAGR during the forecast period. This is attributed to the smooth technological workflow in metabolomics and rapid, precise, reliable, and transparent data processing benefits gained from it.
On the basis of application, the market is segmented into biomarker discovery, drug discovery, nutrigenomics, toxicology testing, personalized medicine, functional genomics, and others. In 2015, the biomarker discovery segment accounted for the largest share of the global metabolomics market. This is mainly attributed to the improvement in both the efficiency and reliability of metabolic profiling of biomarkers and the accurate and clinically useful diagnostic capabilities of metabolic biomarkers for the management of diseases at the metabolic level. However, the personalized medicine segment is expected to register the highest CAGR during the forecast period due to collaborations between pharmaceutical companies and biotechnology firms for biomarker discovery and validation.
In 2015, North America accounted for the largest share of the metabolomics market, followed by Europe. Easy accessibility to technologically advanced products and the presence of a large number of leading metabolomics manufacturers in the region are driving market growth in North America. Similarly, the rising acceptance of personalized medicines, increasing metabolomics research activities, and growing adoption of technologically advanced products are driving the growth of the North American metabolomics market. The Asia-Pacific region is expected to witness the highest growth in this market majorly due to improving biopharmaceutical research infrastructure, large population, rising healthcare needs, growing per capita income, and growing economies in Japan and India. In addition, manufacturers are increasingly focusing on strengthening their presence in emerging markets of APAC countries.
The global metabolomics market is highly competitive in nature, with the top five companies accounting for the major market share in 2015. Some key players in this market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), LECO Corporation (U.S.), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies, Inc. (Japan), and Waters Corporation (U.S.). These leading players have primarily focused on product launches, acquisitions, agreements, collaborations, partnerships, and expansions for growth in the market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact Us: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1–888–600–6441 Email: sales@marketsandmarkets.com
